introduction - the european hematology association (eha) · 2019. 4. 12. · autologous stem cell...

25
Introduction A 32-year-old female Presented with skin blemishes, without ulceration and scratching. These blemishes spontaneously appeared and disappeared from time to time There was no history of systemic B symptoms. The patient did not report any past medical history and no current medication in use. No smoking or excess alcohol drinking

Upload: others

Post on 09-Sep-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Introduction

‒ A 32-year-old female

‒ Presented with skin blemishes, without ulcerationand scratching.

‒ These blemishes spontaneously appeared and disappeared from time to time

‒ There was no history of systemic B symptoms.

‒ The patient did not report any past medical historyand no current medication in use.

‒ No smoking or excess alcohol drinking

Page 2: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Physical examination

A steroid ointment was prescribed by the dermatologist

Page 3: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

History

- Three months latershe noted growing itching plaque with ulceration on the internal part of the right elbow joint.

Page 4: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Q1) How to proceed?

1. Watch & Wait

2. Confocal Laser Scanning Microscopy

3. Local Radiotherapy

4. Skin biopsy

5. Fine needle biopsy

Page 5: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Punch and excisional biopsy

Page 6: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

The skin biopsy was done. In the biopsy material, there were skin fragments with diffuseinfiltration by elements of lymphoid origin. Tumor showed a diffuse growth with polymorphic abnormally shaped nuclei, with light eosinophilic cytoplasm, high epidermotropism andpresence of necrosis

Page 7: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Immunophenotype

➢ CD2+, CD4+

➢ CD3- CD8-

➢ Strong CD30 positivity

➢ CD246 (ALK) -

Page 8: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

CD2 CD4

Page 9: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

CD30

Page 10: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Q2: Which diagnosis?

1. Cutaneous Follicular Lymphoma

2. Sezary syndrome

3. Peripheral T Cell Lymphoma, unspecified

4. Primary cutaneous Anaplastic Large Cell Lymphoma

5. Skin carcinoma

Page 11: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Staging

➢ Peripheral blood flow cytometry analysis showed no evidence of lymphoma or leukemia.

➢ Patient had normal CD4/CD8 ratio and normal expression of B-cell and T-cell antigens.

➢ The whole body CT-scan was negative

➢ No superficial lymph nodes enlargement were noted.

Page 12: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Diagnosis

Primary cutaneous AnaplasticLarge cell lymphoma, ALK negative, Stage I

Page 13: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Q3: Which therapy?

1. CHOP or CHOEP

2. Radiation therapy

3. Steroids

4. PUVA-therapy

5. Brentuximab Vedotin

Page 14: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Treatment

Radiation therapy to ulcerated lesion, locally. Systemic corticosteroids and antihistamine treatment were used to resolve itching.

Imrpvement during RT

Page 15: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

A complete response was achieved after 30 Gy RT

Treatment

Page 16: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Few months later small blemishes were appearing on the skin again

Page 17: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

In a few weeks one of the lesion expanded ..

Page 18: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Q4: Which therapy?

1. CHOP or CHOEP

2. Radiation therapy

3. Low dose methotrexate

4. PUVA-therapy

5. Brentuximab Vedotin

Page 19: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

After 4 courses of

CHOEP treatment was

stopped

Page 20: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

New lesions appeared few months later

Page 21: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Q5: Which therapy?

1. Resume CHOP or CHOEP

2. Bendamustin

3. High dose therapy + Autologous Stem Cell Transplant

4. PUVA-therapy

5. Brentuximab Vedotin

Page 22: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Outcome

‒ Clinical assessment after the first 4 cycles showed a complete disappearance of lesions.

‒ She is still on BV therapy (course # 8)

Page 23: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Discussion

‒ There are many options for treating Primary Cutaneous ALCL available, but localized treatment with either radiation therapy or surgical excision are the preferred therapies for single lesions.

‒ Radiation therapy is most commonly used, and has a response rate of 100%. Radiation therapy has been shown to be be more effective and longer lasting than using multi-agent (“traditional”) chemotherapy.

‒ For multiple or widespread lesions in which radiation therapy or surgery aren’t good options, there are several possible alternatives for treating PCALCL.

Page 24: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

Discussion

‒ For patients with relapse, systemic therapy is recommended.

‒ First line systemic therapy should based on anthracicline containing regimens (CHOP or CHOEP)

‒ For subsequent relapses several alternatives are now available, including the antiCD30 Brentuximab Vedotin

Page 25: Introduction - The European Hematology Association (EHA) · 2019. 4. 12. · Autologous Stem Cell Transplant 4. PUVA-therapy 5. Brentuximab Vedotin. Outcome ‒Clinical assessment

• Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-celllymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentretrial

Prince HM, Kim YH, et al. Lancet June 2017 .